Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations.
Michael J GrantJacqueline V AredoJacqueline H StarrettPaul StockhammerIris K van Alderwerelt van RosenburghAnna WurtzAndrew J Piper-VallilloZofia PiotrowskaChristina J FalconHelena Alexandra YuCharu AggarwalDylan G ScholesTejas PatilChristina NguyenManali PhadkeFang-Yong LiJoel W NealMark A LemmonZenta WaltherKaterina PolitiSarah B GoldbergPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
The ex19del L747_A750>P is associated with inferior PFS compared to the common E746_A750del mutation in patients treated with 1L osimertinib. Understanding differences in osimertinib efficacy among EGFR ex19del.